ArticleAmerican journal of translational research2025
A machine learning model for non-invasive prediction of advanced liver fibrosis in patients with chronic hepatitis B.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Development and validation of a machine learning-based model for identifying liver fibrosis in individuals with prior Schistosoma japonicum infection: a step toward precision management.Infectious diseases of poverty · 2026Article
- Insulin Resistance as a Dynamic Correlate of Fibrosis Status in Chronic Hepatitis B: A Visit-Level Longitudinal Risk Stratification Framework.Life (Basel, Switzerland) · 2026Article
- An interpretable machine learning model for prediction of significant liver fibrosis in comorbid chronic hepatitis B and nonalcoholic fatty liver disease: a retrospective development and validation study.BMC gastroenterology · 2026Article
- Metabolic dysfunction-associated steatotic liver disease as a systemic disorder: extrahepatic manifestations and the need for data-driven phenotyping.Frontiers in endocrinology · 2026Review
- Machine learning-based hepatocellular carcinoma risk prediction model for patients with HBV-related compensated advanced chronic liver disease.Journal of cancer research and clinical oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeChronic Hepatitis B (CHB) is a leading cause of liver fibrosis. Accurate and non-invasive diagnosis of liver fibrosis in CHB patients is of critical clinical importance. This study aimed to develop and validate machine learning (ML)-based models for predicting significant liver fibrosis in CHB patients.
methodsThis retrospective cohort study included 328 CHB patients (225 with non-significant liver fibrosis and 103 with significant liver fibrosis) from 2017 to 2022. Four ML models were constructed based on four selected features identified through the least absolute shrinkage and selection operator (LASSO) regression. Model performance was assessed using the receiver operating characteristic (ROC) curve, and the area under the curve (AUC), accuracy, sensitivity, specificity, and SHapley Additive exPlanations (SHAP) analysis.
resultsThe random forest (RF) model demonstrated the highest predictive performance, with an AUC of 0.874 (95% CI: 0.813-0.934) in the training set and 0.863 (95% CI: 0.772-0.955) in the test set, outperforming extreme gradient boosting (XGBoost), logistic regression (LR), and support vector machine (SVM). Compared with the traditional fibrosis indices such as aspartate aminotransferase to platelet ratio index (APRI) (AUC = 0.585) and fibrosis-4 (FIB-4) (AUC = 0.633), the RF model (AUC = 0.863) demonstrated significantly higher predictive accuracy. SHAP analysis identified platelet count (PLT) as the most influential predictor in the RF model.
conclusionThe ML-based RF model offers a highly accurate, non-invasive interpretable tool for predicting significant liver fibrosis in patients with CHB, offering potential for clinical application in routine fibrosis risk assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.